What Happened?
Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped 9.1% in the afternoon session after investors positioned ahead of a pivotal FDA advisory committee review for its mRNA seasonal flu vaccine.
The FDA's briefing documents for the mFlusiva vaccine struck a balanced tone, easing investor fears after the agency had controversially refused to even review the application earlier this year. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) was expected to meet later in the week to vote on whether the benefits of mFlusiva outweigh the risks for adults aged 50 and older.
In February, the FDA shocked the market by issuing a "refuse-to-file" letter, citing an inadequate comparator trial, before abruptly reversing course days later. The latest briefing documents noted some evidence gaps in older and immunocompromised populations but found no "major deficiencies," which analysts viewed as a highly favorable setup for the panel vote.
Alongside the regulatory relief, Moderna announced an internal reorganization, appointing Ester Banque as Chief Commercial Officer to prepare for up to three new product launches, including a flu/COVID combination and a norovirus vaccine, in 2027 and 2028. The combination of a de-risked regulatory hurdle and a clear commercial roadmap gave the market confidence to bid the stock higher.
Is now the time to buy Moderna? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Moderna’s shares are extremely volatile and have had 45 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 12 days ago when the stock gained 5.1% on the news that the stock's positive momentum was extended as the company, along with partner Merck, presented positive long-term data for its personalized mRNA-based cancer vaccine.
The new five-year results, presented at the American Society of Clinical Oncology's annual meeting, showed significant benefits for patients with high-risk melanoma, a serious form of skin cancer. Findings from the phase 2b trial revealed that patients receiving the vaccine combined with Merck's Keytruda had a 49% lower risk of cancer recurrence or death compared to those treated with Keytruda alone.
The data also showed the treatment reduced the risk of cancer spreading to distant parts of the body by 59%. This news reinforced confidence in the company's mRNA platform beyond its well-known COVID-19 vaccine.
Moderna is up 81.8% since the beginning of the year, and at $56.12 per share, it is trading close to its 52-week high of $57.80 from March 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at only $283.65.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
